Aspire Allergy & Sinus Dr. Haley Overstreet highlights new research on needle-free treatment for severe allergic reactions. Epinephrine saves lives—but too often, hesitation gets in the way. A ...

In a call hosted recently, Nasus Pharma (NYSE:NSRX) presented strong positive topline results from its Phase 2 clinical study ...

Based on real-world data, 92.3% of patients achieved rapid symptom resolution after receiving a single dose of epinephrine nasal spray for systemic reactions. Intranasal epinephrine was found to be ...

Please provide your email address to receive an email when new articles are posted on . Successful treatment of anaphylaxis symptoms with a single dose of neffy 2 mg was found in 89.2% of patients in ...

NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a ...

neffy is the first epinephrine product approved for use out of a hospital setting in China for adults and children (>30 kg) living with severe allergic reactions Pediatrix Therapeutics, which has a ...

Nasus Pharma Ltd. NSRX shares are down on Wednesday following the company's continuous weakness after the announcement of ...

Aug. 9 (UPI) --The U.S. Food and Drug Administration on Friday announced the approval of the first nasal spray for treatment of anaphylaxis, a life-threatening allergic reaction. The epinephrine nasal ...

A multicenter study found that a 2-hour monitoring period was sufficient for most children who presented to the emergency department with an acute allergic reaction treated with epinephrine. However, ...

The first non-injectable emergency treatment for allergies is anticipated to hit shelves following FDA approval of the neffy epinephrine nasal spray. The product from ARS Pharmaceuticals, previously ...

ANAHEIM, California — Paramedics who respond to emergency calls for patients with signs and symptoms of acute allergic reaction and anaphylaxis are failing to give life-saving epinephrine, according ...